PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.77%
Negative EBIT growth while CRVO is at 690.75%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-6.04%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-65.74%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-47.67%
Negative EPS growth while CRVO is at 100.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-53.82%
Negative diluted EPS growth while CRVO is at 100.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
12.14%
Slight or no buybacks while CRVO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
7.50%
Slight or no buyback while CRVO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-13.29%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-13.04%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24856.69%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19589.97%
Negative 5Y OCF/share CAGR while CRVO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
63.13%
3Y OCF/share CAGR of 63.13% while CRVO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-19587.84%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-19245.92%
Negative 5Y net income/share CAGR while CRVO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
62.10%
3Y net income/share CAGR of 62.10% while CRVO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
30196.53%
Equity/share CAGR of 30196.53% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
5954.03%
Equity/share CAGR of 5954.03% while CRVO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
827.17%
Equity/share CAGR of 827.17% while CRVO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.14%
Positive asset growth while CRVO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-14.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
28.86%
SG&A declining or stable vs. CRVO's 519.26%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.